Merck's diabetes drug Januvia succeeds in heart safety trial

April 27, 2015 9:29 PM

8 0

April 27 (Reuters) - Merck and Co's diabetes drug Januvia achieved the main goal of a long-awaited heart safety study, according to preliminary results released by the company on Monday, likely removing a cloud of uncertainty from its biggest product.

In after-hours trading, Merck shares rose nearly 4 percent after the announcement on Januvia, which had sales of about $4 billion in 2014.

Also read: Chinese-Mexican businessman remains in prison awaiting trial

Read more

To category page